Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Ural
A Ugur
AU
Avcu
Ferit
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004164:Diphosphonates / Q000008:administration & dosage; D000077143:Docetaxel; D004357:Drug Synergism; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid